NCT05096702: Trust

Operational Feasibility of Appropriate Radical Cure of Plasmodium Vivax With Tafenoquine or Primaquine After Quantitative G6PD Testing in Brazil

Status unknown Last updated 13 June 2023

What this trial tests

trial testing Tafenoquine in Malaria, Vivax in 16,000 participants. Status unknown.

Timeline

9 September 2021

Primary endpoint
30 August 2022

9 September 2023

Quick facts

Lead sponsor	Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	16,000
Start date	9 September 2021
Primary completion	30 August 2022
Estimated completion	9 September 2023
Sites	41 locations across Brazil

Drugs / interventions tested

• Tafenoquine (TAFENOQUINE) — full drug profile →
• Primaquine — full drug profile →
• Primaquine — full drug profile →

Conditions studied

• Malaria, Vivax — all drugs for Malaria, Vivax →
• G6PD Deficiency — all drugs for G6PD Deficiency →

Sponsor

Fundação de Medicina Tropical Dr. Heitor Vieira Dourado

Who can join

Eligibility, any sex, with Malaria, Vivax or G6PD Deficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an observational study carried out in Brazil in patients with P. vivax malaria. The study will be carried out in the municipalities of Manaus (state of Amazonas) and Porto Velho (state of Rondônia).

G6PD and TQ tests will be provided to health facilities by municipal health authorities using the common route for the provision of drugs and diagnostics. PQ and other antimalarial drugs are already available in Brazil.

Designated personnel at the health facilities will be trained to perform the G6PD quantitative test procedure and the radical healing treatment algorithm by the Lead Researcher (RP) team and municipal authorities using teaching materials developed by the sponsors.

The study design is based on the secondary use of data routinely collected from all malaria patients in the Epidemiological Surveillance Information System for Malaria (SIVEP-Malaria) by the Ministry of Health (MS). Data from all malaria patients are routinely collected through SIVEP forms by health professionals (HP) and entered into the SIVEP database by the municipality staff.

The SIVEP form will be adapted by the MS to collect information about the G6PD test, TQ treatment and signs of hemolysis. The retrospective data from all patients will be entered into a new database by the municipality staff during the study period and the relevant data will be automatically exported weekly to the SIVEP database. The study team will only have access to unidentified data, according to the access levels that will be assigned to each member in the system. Only the municipality's team will have access to the identified patient data. In addition to the data collected on the SIVEP forms, the PR team will ask the two referral hospitals that routinely receive all admissions due to AHA to perform a regular screening of electronic hospital admission records for patients with signs of AHA (renal failure, jaundice, blood transfusion, malaria). All identified cases will be investigated using hospital records and SIVEP forms. Confirmed information about drug-induced AHA will be linked to the patient record recorded in the database. The PR team will also contribute to pharmacovigilance training. Physicians at tertiary-level health units will report side effects through the VigiMed system, from the National Health Surveillance Agency (ANVISA).Finally, the additional costs of implementing the G6PD and TQ tests will be collected along with the study at the health facilities.

Since the study is based on retrospective data collection, and the adoption of TQ and G6PD testing will be done by the municipality, the G6PD testing and the treatment of patients with TQ or PQ will be carried out in accordance with the treatment policy , that is, regardless of the study.

The study will be carried out in phases:

\- 1st phase (approximately 3 months): Training and provision of G6PD and TQ tests will initially be limited to 10 high-complexity and intermediate-complexity units (referral hospitals, hospitals, emergency care units, polyclinics). Data will be collected from patients with P. vivax treated at these health facilities.

An interim analysis will be performed after collecting data from 600 patients with P. vivax ≥ 16 years, who have not been treated for vivax malaria in the past 60 days, in the study database in order to decide whether the study can be extended to less complex health units. The decision will be made by an Independent Study Oversight Committee (ISOC).

If the interim results of Phase 1 are found to be unsatisfactory, ISOC may decide not to extend the study to primary care units until improvements in the educational program are implemented and/or additional support is provided to health professionals. Additional interim analyzes will be performed as appropriate.

\- 2nd phase (approximately 9 months) \[CURRENT PHASE\]: if approved by ISOC, the study will be extended to less complex health units (basic health units, family health units and other primary care services) and other high and medium complexity of health in the selected municipalities. After staff training, G6PD and TQ testing will be provided to these health facilities by municipal health authorities.

During this 2nd phase, data will continue to be collected from patients with P. vivax treated by the 1st phase tertiary care units.

\- An additional interim analysis will be performed after data from 600 patients with P. vivax ≥16 years old, who have not been treated for P. vivax malaria in the past 60 days, from primary care units are collected in the study database ( approximately 3 months after the start of the 2nd phase).

The study will continue while the interim analyzes are being carried out. Final results will be analyzed and validated by ISOC. The study is expected to take approximately 15 months.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

1. Operational effectiveness of tafenoquine and primaquine for the prevention of Plasmodium vivax recurrence in Brazil: a retrospective observational study.
   Brito M, Rufatto R, Brito-Sousa JD, Murta F, et al · · 2024 · cited 27× · PMID 38452779 · DOI 10.1016/s1473-3099(24)00074-4
2. Operational feasibility of Plasmodium vivax radical cure with tafenoquine or primaquine following point-of-care, quantitative glucose-6-phosphate dehydrogenase testing in the Brazilian Amazon: a real-life retrospective analysis.
   Brito M, Rufatto R, Murta F, Sampaio V, et al · · 2024 · cited 27× · PMID 38365417 · DOI 10.1016/s2214-109x(23)00542-9
3. Association of G6PD status and haemolytic anaemia in patients receiving anti-malarial agents: a systematic review and meta-analysis.
   Nelwan EJ, Shakinah S, Pasaribu A. · · 2023 · cited 7× · PMID 36872344 · DOI 10.1186/s12936-023-04493-7
4. An observational pilot study of an active surveillance tool to enhance pharmacovigilance in Brazil.
   Pereira DB, Lacerda MVG, Bilkhu P, Duarte C, et al · · 2025 · cited 2× · PMID 40033382 · DOI 10.1186/s12936-025-05295-9